The efficacy of Gabapentin in chronic refractory cough in Interstitial Lung Disease
- Conditions
- Health Condition 1: J849- Interstitial pulmonary disease, unspecified
- Registration Number
- CTRI/2024/07/071040
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients aged 18 years to 70 years of age. Individuals classified with interstitial lung disease according to the most recent diagnostic criteria established by the American Thoracic Society. Patients with chronic intractable cough, that is cough more than eight weeks with a severity of more than 40mm on VAS score. Patients with no contraindications to Gabapentin treatment
Patients who give negative informed consent. Patients with exposure to Gabapentin or Pregabalin within 2 months. Upper respiratory tract infection within 2 months. Current or ex-smokers. Patients presenting with acute exacerbation of ILD. Patients with co-morbidities like Obstructive airway disease, Gastroesophageal reflux disease or Congestive Cardiac Failure.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean LCQ scores in study group and control groupTimepoint: Baseline, 4, 8 and 12 weeks
- Secondary Outcome Measures
Name Time Method 1. Cough severity score (VAS SCORE) in study group and control group <br/ ><br>2. Modified Borg‘s Dyspnea score in the study group and control group <br/ ><br>3. Occurrence of adverse events (AE) / Severe adverse events (SAE) <br/ ><br>4. After discontinuation of Gabapentin, change in LCQ and VAS score after 4 weeks.Timepoint: Baseline, 4, 8 and 12 weeks